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Objectives: To evaluate the acceptance, effectiveness in preventing upper airways obstruc-
tion, and haemodynamic effects of continuous positive airway pressure (CPAP) in acute stroke.
Methods: Twelve patients (4 M, and 8 F; mean (SD), 75.2 (5.5) years) within 48 h of acute
stroke onset underwent: (1) sleep studies (1st night: auto-CPAP mode; 2nd night: diagnostic);
(2) nocturnal non-invasive blood pressure studies (1st night during CPAP; 2nd night during spon-
taneous breathing (SB)); and (3) daytime cerebral blood flow velocity measurement in middle
cerebral artery (FV) with transcranial Doppler during SB and with CPAP (5, 10, 15 cmH2O).
Results: Ninety percent, 60% and 50% of stroke patients had a respiratory disturbance index (RDI)
of5,10and15eventsperhour, respectively (18.2 (11.3)).CPAPacceptancewas84%;42%used
CPAPmore than6 hand42%between1e3 hwithameanuseofCPAPof 5.2 h (4.0).Compared to SB,
CPAP reduced, though not significantly, RDI, timewith SaO2< 90%,mean blood pressure andmean
blood pressure dips (10 mmHg)/h. Compared with SB, any level of CPAP progressively and signifi-
cantly reduced systolic and mean FV; drop in diastolic FV was significant at CPAP10 and CPAP15.
The partial pressure of end-tidal CO2 was significantly lowered by all levels of CPAP.
Conclusions: According to this pilot study, CPAP is reasonablywell tolerated by patientswith acute
stroke for at least one night. Despite its possible beneficial effect on obstructive sleep-disordered
breathing and blood pressure variability, CPAP use in acute stroke should be still considered with
caution due to possible harmful haemodynamic effects at higher pressures.
ª 2008 Elsevier Ltd. All rights reserved.75254541, þ39 3482605980; fax: þ39 0575254545.
tmail.com (R. Scala).
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60 R. Scala et al.Introduction MethodsThere is an emerging evidence base of an association
between sleep-disordered breathing (SDB) and cerebro-
vascular disease, suggesting that obstructive sleep
apnoea (OSA) is an independent risk factor for stroke
proportional to severity.1e7 The relationship between OSA
and stroke is further supported by several studies which
found a significant prevalence of SDB (especially OSA)
(43e95%) in patients with recent cerebrovascular acci-
dents.7e16 It is not clear whether SDB may be regarded as
a consequence of, or as a cause of stroke, or both.
Regardless of whether SDB precedes or follows a stroke,
some data suggested that it may adversely affect both
the functional outcome at 3 and 12 months8 and the
mortality at 6 months, 2 and 4 years7,17,18 of patients
with acute stroke. Moreover, recent studies demonstrated
that sleep-related stroke and the early neurological
worsening of stroke were independently predicted by the
degree of respiratory disturbance index (RDI) and by the
presence of SDB, respectively.13,16
Only two studies12,13 showed a high prevalence of
SDB, mostly due to obstructive events, within the first
24 h of stroke, when the critical phenomenon of the
ischaemic penumbra is taking place.19 In the acute phase
of stroke the physiological consequences of recurrent
obstructive apnoeas may have the most deleterious
effect on critically ischaemic, but viable, brain tissue
and, therefore, may adversely affect prognosis. Systemic
and cerebral haemodynamic fluctuations and/or episodes
of hypoxia are known to accompany occlusion of the
upper airway in patients without stroke. Specifically,
systemic blood pressure (BP), pulse rate and cardiac
output all decrease during an obstructive apnoea and
increase suddenly when arousal ends the apnoea.20
Moreover, cerebral blood flow velocity decreases during
upper airway obstruction21 and cerebrovascular reac-
tivity is impaired in OSA patients.22
We postulated that application of continuous positive
airway pressure (CPAP) would be the treatment of choice
for OSA23 in the first hours after stroke. CPAP may reduce
morbidity and mortality by preventing episodes of upper
airway obstruction and their haemodynamic and hypox-
emic effects upon ischaemic cerebral tissue. To confirm
this hypothesis, a prospective interventional trial is
needed. However, CPAP in the acute phase of stroke
could have harmful effects. Firstly, application of CPAP in
patients with acute stroke may be problematic for
several reasons (i.e., age, cognitive and communication
deficits, facial palsy). Secondly, BP may be reduced by
CPAP in patients in whom cardiac output is likely to be
preload-dependent and who may be dehydrated.24
Thirdly, as in healthy subjects,25 cerebral blood flow
velocity may drop with CPAP due to hypocapnia-induced
cerebral vasoconstriction.
This pilot study aims to establish: (1) the feasibility of
delivering CPAP to patients in the acute phase of stroke; (2)
the effectiveness of CPAP in preventing obstructive events
and its associated cardiovascular fluctuations; and (3) the
safety of CPAP in terms of systemic and cerebrovascular
haemodynamics.Patients and study design
We prospectively studied 12 consecutive patients with
a clinical and CT-based diagnosis of acute stroke admitted
to the Stroke Unit of the Leeds General Infirmary. Inclusion
criteria were: symptom onset< 48 h; body mass index> 22
Kg/m2; and neck circumference> 34 cm (female) and >37
cm (male). The study was carried out in accordance with
the Declaration of Helsinki (2000) of the World Medical
Association and was approved by the Ethics Committee of
the Hospital; informed, written consent was obtained from
all patients or, if they were unable, their next of kin.
Consent was sought as soon as possible after admission and
the studies were started directly thereafter. Exclusion
criteria were: vomiting since stroke; uncontrolled agitation
or confusion; and refusal of consent.
The design of the study consisted of (1) titration and
diagnostic sleep studies; (2) non-invasive BP overnight
studies (1st night during CPAP; 2nd night during sponta-
neous breathing (SB)); and (3) daytime cerebral blood flow
velocity measurement in the middle cerebral artery (FV)
with transcranial Doppler (TD) during SB and at increasing
levels of CPAP.
Patient assessment
On admission all patients underwent a comprehensive
assessment that included: age, sex, body mass index, neck
circumference, history of snoring, previous cerebrovascular
accidents, hypertension, diabetes mellitus. Daytime
sleepiness preceding stroke was estimated by the Epworth
Sleepiness Scale (ESS).26 Pre-stroke disability and handicap
were assessed with the Barthel Index27 and the modified
Rankin Scale, respectively.28
Diagnosis and location of stroke was confirmed by means
of a CT brain scan performed within 72 h of admission to the
Stroke Unit. Stroke subtypes were clinically classified
according to the Oxford Community Stroke Project29: total
anterior circulation syndrome (TACS), partial anterior
circulation syndrome (PACS), lacunar syndrome (LACS), and
posterior circulation syndrome (POCS). Stroke severity was
assessed using the Scandinavian Stroke Scale.30 Level of
consciousness (Glasgow Coma Scale),31 limb weakness
(Motricity Index)32 and the modified Rankin Scale28 were
documented on admission.
Titration and diagnostic sleep studies
Sleep studies were performed with the Autoset Portable II
Plus (ResMed, Sydney, Australia), which allows both diag-
nostic and CPAP titration of patients with SDB.33 Several
investigations reported a similar accuracy of a portable,
automatic CPAP device compared to conventional poly-
somnography.34e36 Furthermore, Bassetti et al16 found
a good correlation (r2Z 0.75) between the apnoeae
hypopnoea index as estimated by polysomnography and
automatic CPAP device in 31 acute stroke patients.
As soon as possible, after recruitment to the study, an
explanation of CPAP was given to the patients; they then
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choosing an interface (nasal or facial mask; Sullivan; Mirage
ResMed) and establishing the maximum pressure which
could be tolerated without significant leak. During the first
night patients received CPAP in automatic mode33 with
lower and upper pressure limits of 4 and 10 cm cmH2O,
respectively; this was switched to manual mode if the
automatic mode was not tolerated. Oxygen saturation and
heart rate (finger pulse oximeter probe), snoring, airflow
and flow limitation (pressure transducer), body position and
respiratory effort (strain gauge) were recorded. Usual
nursing care, patient positioning included, was not changed
during the study. Nursing staffs were instructed to check
CPAP acceptance throughout the night. To avoid increasing
distress to the patients in this critical phase after stroke,
CPAP was taken off when any signs of discomfort became
evident. CPAP acceptance rate was expressed according to
the number of hours tolerated, as ‘‘higher’’ (H) or ‘‘lower’’
(L) than 3 h. Refusal of CPAP occurred if patients did not
tolerate the machine for more than 1 h.
The second night following recruitment, the patients
underwent a diagnostic study (mean (SD) length, 6.2 h
(2.5)) during SB with the same device but with nasal
cannulae positioned to measure nasal airflow instead of the
CPAP mask.
Each study was individually performed and scored by the
same physician (RS). RDI was subsequently calculated as the
number of apnoeas and hypopnoeas per hour of study. An
apnoea was scored if the 2-s moving average ventilation
dropped below 25% of the recent average (time constant
100 s) for 10 s. An hypopnoea was defined as a 50e75%
decrease in ventilation for 10 s. The analysis was limited to
obstructive events since the identification of central events is
not reliable with this diagnostic portable device.33 The
severityofSDBwasclassifieddependingonthe levelofRDI5,
10and15events per hour. Index of 4%oxygendesaturation
and percentage of time with SpO2< 90% were also recorded.
Non-invasive haemodynamic nocturnal studies
Beat to beat non-invasive BP was monitored with the Por-
tapres model 2 device (TNO-TPD, Biomedical Instrumenta-
tion)37 during CPAP (first night) and during SB (second
night). The Portapres device is based on the arterial volume
clamp method of Pe´n˜az and measures BP through two small
finger cuffs wrapped around the middle and ring fingers of
the hand of the dominant arm, which are alternately used
every 30 min to avoid the discomfort associated with pro-
longed measurements from one finger only. The device also
includes a system capable of automatically correcting for
changes in finger pressure induced by changes in the level
between the heart and the instrumented finger, due to
hand displacement. All data were analysed off-line; analog
signals were A/D converted with a 0.25 mmHg resolution at
100 Hz real time and analysed by dedicated software
(BeatScope, TNO-TPD, Biomedical Instrumentation).
Systolic, diastolic, mean BP, as well as pulse interval and its
inverse, pulse rate, were derived from each single pulse
wave by the Beatfast program. All data were averaged by
time in seconds; the recorded segments containing the
automatic calibration signal and artefacts were removed
from the Portapres traces.To investigate BP variability we calculated the number
of mean BP dips 10 mmHg/h as the mean difference
between the mean BP value of a single pulse and the
average of mean BP of the previous 10 pulses.
Cerebral blood flow velocity measurements
in the middle cerebral artery
Systolic, diastolic and mean FV were assessed by using
a 2 MHz-pulsed TCD device (SciMed PCDop 842AQ; SciMed,
Bristol, UK). After the diagnostic sleep study, each subject
was investigated during the day while awake and supine
during SB and CPAP, via a nasal or a facial mask. Using
a previously described protocol,25 all subjects were exam-
ined for 3 min in each of the following stages: before (SB)
and with increasing levels of CPAP (Sullivan ResMed UK
Ltd.) at 5, 10 and 15 cmH2O (CPAP5, CPAP10, CPAP15)
taking care to avoid air leaks.
The probe, fixed with an elastic headband, was placed
over the temporal bone, just above the zygomatic arch in
order to obtain a continuous measurement of FV. The M1
segment of the middle cerebral artery was sought at
a depth of approximately 50 mm, keeping the insonation
angle constant throughout the investigation.38 Measure-
ment was performed on one or both sides depending on
patient tolerance. The test was interrupted if the patient
showed any signs of discomfort. Partial pressure of end-
tidal CO2 (PetCO2) was recorded continuously with an
infrared analyser (Morgan Capnograph, PK Morgan Ltd.,
Rainham, Kent, UK). In order to minimise the potential
error of dilution on PetCO2 measurement due to the CPAP
bias flow, a thin catheter was inserted through a T-tube
situated between the mask and the expiratory port; the
end of the catheter was positioned just into one nostril.
Particular attention was paid to obtain a reliable capno-
graphic trace throughout the tests.25
Statistical analysis
All data are expressed as mean (SD) except for ordinal data
derived from various scales which are described as median
(interquartile range (IQR)). Statistical comparisons were
made with two-tailed Student’s t-test or ManneWhitney or
Chi-square test where appropriate. For multiple compar-
ison of FV and PetCO2 at the different stages of TCD study
the repeated measures ANOVA test was applied. SB values
were compared with CPAP5, CPAP10, CPAP15 values by
means of post hoc analysis (Bonferroni test) if the ANOVA
test was significant. Correlation between percentage
changes of FV and PetCO2 were tested with linear regres-
sion by applying the least-squares method.
A value of p< 0.05 was assumed to be statistically
significant. Analyses were performed using version 10.0 of
the SPSS statistical software package for Windows (SPSS,
Inc., Chicago, Illinois).
Results
All patients enrolled in the study had a diagnosis of
ischaemic stroke confirmed clinically and radiologically.
Demographic and pre-stroke clinical characteristics of the
62 R. Scala et al.population studied are shown in Table 1. Some of the
recruited patients could not fill in the ESS questionnaire
independently, but all of them were able to read and/or
understand the items of the ESS and to answer the ques-
tions with support. Although it has not been validated for
use in this way it was not an end point in this study, but
rather was used to help define the study population.26
Delay from estimated time of onset of first stroke symptom
and start of the CPAP sleep study was 21.8 h (15.5).
Admission to the emergency department occurred 3.3 h
(3.8) after symptom onset. Stroke features are described in
Table 2. Fig. 1 shows the study protocol.
Titration and diagnostic sleep studies
Acceptance of CPAP was reported in 84% of cases (10/12)
with a mean use of CPAP of 5.2 h (4.0) (range 1.5e11).
Refusal of CPAP in two cases was due to claustrophobia and
agitation within 30 min of CPAP application. Causes of CPAP
withdrawal in L group were: late onset mask discomfort (3
cases), excessive air pressure (1 case), and mask dislodge-
ment (1 case). A nasal mask was used in 6 cases; in two
cases CPAP was switched from automatic to manual mode.
The median pressure in the 10 patients who accepted CPAP
was 6 cmH2O (1.7) (95th percentile, 8 cmH2O (1.6)); the
pressure waves in the downloaded graphs did not show long
periods of plateau at upper pressure limit as if central
events were the most prevalent sleep pattern. Compared to
L group, patients of H group showed a trend towards
a greater sleepiness score (12 (5e12.5) versus 7 (5e12.5)),
worse stroke severity (38 (11e46) versus 24 (18e41)) and
greater limb weakness (122 (0e182) versus 74 (0e136)).
The diagnostic sleep study was performed 48.2 h (16)
after the estimated onset of stroke symptoms in all but two
cases: one with a high acceptance of CPAP in the first night
had a sudden respiratory arrest the following day due to
a further brainstem stroke; another patient, who did not
tolerate CPAP, refused to continue the study. Ninety
percent, 60% and 50% of stroke patients had an RDI of 5,Table 1 Demographic and pre-stroke clinical characteristics.
Variable Value
Age, yrs 75.2 (5.5)
Sex, n (%) male 4 (33.3)
Body mass index, kg/m2 26.6 (4.7)
Neck circumference, cm 41.2 (4.5)
Epworth Sleepiness
Scale, median (IQR)
10.5 (6.3e13)
History of snoring, n (%) 9 (75)
Hypertension, n (%) 6 (50)
Diabetes mellitus, n (%) 1 (8.3)
Modified Rankin
score, median (IQR)
2 (1.25e2)
Barthel Index,
median (IQR)
16.5 (14e18.8)
All data are expressed as mean (standard deviation) unless
differently stated.
IQR: interquartile range.10 and 15 events per hour, respectively (mean (SD), 18.2
(11.3)). CPAP acceptance in patients with higher degrees of
SDB (RDI 10) was 83.3% (5/6 patients) with a mean use of
3.7 h (4.1).
Table 3 shows the sleep studies data. In 9 patients
compliant to CPAP (L and H groups), there was a non-
significant trend to a reduced RDI (17.7 (12.5) versus 11.3
(8.8)) and time with SaO2< 90% (8.1 (14.7) versus 0.6 (0.9))
in the SB versus CPAP assessments.
Non-invasive BP nocturnal studies
Haemodynamic monitoring was performed both during
CPAP and SB nights in 8 of 10 patients adherent to CPAP.
A trend towards a drop in mean BP and in BP variability was
observed during CPAP (Table 4).
Cerebral blood flow velocity measurements
in the middle cerebral artery
Fourteen measurements of FV were obtained in 9 patients
all with RDI 5 event per hour (7 were recorded from the
affected cerebral side); in 5 subjects the study was per-
formed on both sides. Measurements were made 53.1 h
(23.4) after the estimated time of stroke symptoms onset,
once the second sleep study was ended. In most cases (11/
14) a facial mask was used. EtCO2 trace was reliable in 8
cases.
Compared to SB, any level of CPAP progressively and
significantly reduced systolic and mean FV; the drop in
diastolic FV was significant at CPAP10 and CPAP15. PetCO2
was significantly lowered by all levels of CPAP (Table 5).
The fall in systolic FV was significantly correlated with the
reduction in PetCO2 at CPAP10 (rZ 0.861; pZ 0.006).
Discussion
This pilot study was conducted within the first 48 h of
acute stroke in 12 patients with the aims of clarifying
whether CPAP is feasible, effective in preventing
obstructive events and its associated cardiovascularTable 2 Stroke characteristics.
Variable Value
First stroke, n (%) 6 (50)
Scandinavian Stroke Scale 31 (17e42)
Motricity index 97 (0e151.8)
Modified Rankin score 5 (4e5)
Glasgow Coma Scale 15 (13e15)
TACS, n (%) 5 (41.7)
PACS, n (%) 3 (25)
POCS, n (%) 0 (0)
LACS, n (%) 4 (33.3)
All data are expressed as median (interquartile range) unless
differently stated.
TACS: total anterior circulation syndrome; PACS: partial anterior
circulation syndrome; POCS: posterior circulation syndrome; and
LACS: lacunar syndrome.
12 pts with
acute stroke onset <48 hours
10 pts accepted CPAP 
(>1 hour/1st night)
2 pts refused CPAP
(<1 hour 1st night)
9 pts completed
diagnostic sleep study (2nd night)
8 pts completed 
BP study both in SB and CPAP 
9 pts completed 
transcranial doppler study 
1 pt completed
diagnostic sleep study (2nd night)
Figure 1 Flow chart of the study protocol. CPAPZ continuous positive airway pressure; SBZ spontaneous breathing; BPZ blood
pressure.
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vascular haemodynamics. It was confirmed that SDB was
common in the acute phase of stroke, with 60% of patients
having RDI of 10 events per hour. The acceptance rate of
CPAP was variable with 42% of patients using the machine
for >6 h and 42% for 1e6 h. In the patients who used CPAP,
there was a trend to a reduced RDI and length of time with
SaO2 below 90%. Non-invasive systemic haemodynamic
monitoring showed a non-significant reduction in both
mean BP and BP fluctuations during CPAP compared to SB.
FV measured during the day was significantly impaired by
increasing levels of CPAP given for a short trial, which also
caused significant hypocapnia.
The prevalence of SDB found in our study was similar to
that reported by other authors in acute stroke (<5 days
since symptom onset).12e14 As our study protocol involved
additional equipment for the haemodynamic investigation,
we performed the diagnostic sleep study with a limited,
less complicated but validated system (Autoset Portable II
Plus)16,34e36 because more intrusive full polysomnography
would have not been tolerated by agitated and dependent
stroke patients.11 However, sleep duration, stage and
quality cannot be assessed with this kind of respiratory
variable-only monitoring systems. Moreover, central sleep
apnoea and/or CheyneeStokes respiration (CSA/CSR),
which may occur in acute stroke,9 could not be detected
with the Autoset diagnostic system. However, studies of
SDB in acute stroke show that most events are obstructiveTable 3 Sleep studies data.
SB CPAP p-value
Time with
SaO2< 90%, %
16.7 (29.2) 0.6 (0.9) >0.05
Oxygen 4% desaturation
index, n/h
18.1 (9.4) 9.7 (10.7) >0.05
RDI, n/h 18.2 (21.3) 10.9 (8.4) >0.05
RDI> 10, n (%) 6 (60) 4 (40) >0.05
All data are expressed as mean (standard deviation), unless
differently stated.
SB: spontaneous breathing; CPAP: continuous airway pressure;
and RDI: respiratory disturbance index.with central events being uncommon7,8,10,12,14 except in
patients with coexistent left ventricular dysfunction.39
Because the denominator for the calculation of RDI is total
study time rather than total sleep time, the Autoset tends
to underestimate the severity of SDB.
Our finding of 42% of all patients included into the study
with high acceptance of CPAP with the Autoset system is
similar to the results of the previous investigations per-
formed in the earlier phase of the stroke (47e69%)14,16 and,
not surprisingly, lower than those reported in the rehabili-
tation post-stroke setting in selected and much younger
patients (70.5e100%).15,40,41 This study reports the first
patients treated with CPAP in our unit and inevitably there
was a learning curve. It is probable that with increasing
familiarity, particularly of the nursing staff, acceptance
and compliance would increase.
Interestingly, in our study, patients with better toler-
ance of CPAP showed a trend towards a greater sleepiness
score, worst stroke severity and greater limb weakness.
Likelihood of pre-stroke OSA (i.e., greater sleepiness score)
and severe motor defect may improve the acceptance of
CPAP in acute stroke. Statistical analysis did not reach
significance for these variables probably due to the small
size of the sample.
The lack of a significant effect of CPAP on SDB may be at
least in part due to the occurrence of CSA/CSR in our
patients as well as to the small size of the sample. It has
been shown that ‘‘pure’’ CSA/CSR events may be more eff-
ectively managed by the use of adaptive servo-ventilationTable 4 Haemodynamic nocturnal data.
SB CPAP p-value
Systolic BP, mmHg 155.8 (17.1) 140.8 (34.9) >0.05
Diastolic BP, mmHg 69.9 (11.8) 70.1 (20.8) >0.05
Mean BP, mmHg 98.6 (7.2) 94.2 (22.6) >0.05
Mean BP dips 10
mmHg h1, n
299 (227) 219 (110) >0.05
All data are expressed as mean (standard deviation).
SB: spontaneous breathing; CPAP: continuous airway pressure;
and BP: blood pressure.
Table 5 Transcranial Doppler data.
SB CPAP5 CPAP10 CPAP15 Significancea
Systolic FV cm s1 66.9 (27.6) 60.4 (28.3)b 58.4 (28.1)b 50.6 (22.4)b pZ 0.001
Diastolic FV cm s1 20.3 (12.3) 19.0 (11.7) 18.6 (11.1)b 16.8 (8.5)b pZ 0.045
Mean FV cm s1 36.5 (18.0) 33.6 (18.5)b 32.5 (17.2)b 28.7 (13.5)b pZ 0.007
PetCO2 Kpa 5.6 (1.5) 5.0 (1.3)
b 4.7 (1.2)b 4.4 (1.2)b p< 0.0001
All data are expressed as mean (standard deviation).
SB: spontaneous breathing; CPAP: continuous airway pressure; FV: cerebral blood flow velocity; and PetCO2: and end-tidal CO2 partial
pressure.
a Represents significance as measured by repeated measures ANOVA test.
b Represents significant changes from baseline value as measured by post hoc analysis.
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in breathing pattern, sleep quality and stability of PaCO2
level.42
All patients had CPAP followed by a diagnostic study and,
while this might seem illogical, if CPAP is to have an effect on
the ischaemic penumbra, it must be started as soon as
possible. For the purposes of this pilot study it was important
to understand whether these patient did indeed have upper
airway obstruction and to understand the effect of CPAP on
SDB and haemodynamics. In future randomized controlled
trials, patients would either have CPAP or a diagnostic study
on the first night. Secondly, we performed the CPAP titration
before the sleep diagnostic study in order to avoid an over-
estimation of CPAP effects on SDB. Stroke patients might
show spontaneous improvement between study nights as any
acute cerebral oedema resolves.9
A trend of reduction in overnight mean BP, and in its
variability, was observed with CPAP in acceptant patients.
Effective CPAP which prevents obstructive events and their
physiological consequences, such as hypoxemia and
cardiovascular fluctuations, may reduce the damage to the
ischaemic, but viable, penumbra in the crucial first hours of
acute stroke.19 On the other hand, the finding of a trend
towards a drop in BP with CPAP could have harmful effects
upon cerebral perfusion in ischaemic tissue. In fact, as
autoregulation may be locally impaired in acute stroke,43
cerebral perfusion may become ‘‘pressure-dependent’’.
Moreover, FV as measured with TCD was reduced by
increasing levels of CPAP; FV allow a good estimation of
cerebral blood flow as it is widely accepted that changes in
cerebral perfusion through the large arteries on the surface
of the brain, such as the middle cerebral artery, are mainly
due to changes of velocity, with only insignificant changes
of vessel diameter.38 In acute stroke, these cerebrovascular
changes with CPAP could enhance the negative effects of
falls in systemic blood pressure upon ischaemic cerebral
tissue. As we found in normal subjects,25 the CPAP-induced
FV drop was associated with a reduction in PetCO2 in stroke
patients; so the effect of CPAP upon FV might be at least
partially due to the constriction of small cerebral resistance
vessels because of hypocapnia.
Some important issues have been raised by this study.
The potential for CPAP, certainly at higher levels, to result
in undesirable physiological changes, is confirmed, though
it is not known whether the fall in BP and FV seen in the
daytime study are clinically relevant. The interpretation of
the effects on FV should be made with caution as they were
obtained after a short trial of CPAP. Patients breathing witha mask when it is first put on may hyperventilate, though of
note by the time the transcranial Doppler study was per-
formed they had used CPAP overnight, lowering carbon
dioxide and affecting FV. This hyperventilation may not be
sustained with longer use or during sleep overnight. The
effects were not surprisingly more marked at higher CPAP
pressures, although any potential harmful effects may be
offset by the beneficial effects of abolishing obstructive
SDB and its haemodynamic sequelae and hypoxia. It would
seem reasonable in any future studies to cap CPAP pressure
at 10 cmH2O, as pressures above this level may have
harmful haemodynamic effects and do not seem to be
necessary anyway to control the sleep-disordered breathing
(mean CPAP pressure of 6 cmH2O in the sleep study).
Even though oxygen therapy may have a role in cor-
recting, at least partially, hypoxemia induced by CSA/
CSR, it has no effects on severe obstructive events and
would have no effect on the blood pressure fluctua-
tions.42 Preventing hypocapnia by the addition of CO2 to
the circuit prevents the CPAP-induced fall in FV in
normal subjects25 and this could be achieved by reposi-
tioning of the exhaust port in the CPAP circuit to
increase the dead space and, therefore, rebreathing.
Any CPAP-induced fall in BP might be prevented by
ensuring adequate hydration and avoidance of hypoten-
sive agents.
Our data suggest that CPAP is reasonably well tolerated
by patients with acute stroke for at least one night, but do
raise some concerns about possible harmful effects at
higher pressures. Larger scale studies should now be
undertaken to test the hypothesis that CPAP can reduce
secondary damage to the ischaemic penumbra due to
obstructive SDB-induced cardiovascular variability and
hypoxia.
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